Further growth for regulatory affairs team at Boyds with appointment of Harriet Edwards
We are pleased to announce the appointment of experienced regulatory professional, Harriet Edwards, in response to a sustained rise in demand for specialist regulatory services and expertise. With more than nine years’ experience in regulatory affairs across generic pharmaceuticals, early stage clinical CROs and biotech companies, Harriet joins Boyds as Associate Director of Regulatory Affairs. […]
Rare Disease Day: Gene therapy trends and innovation for rare diseases
To mark Rare Disease Day 2023, Professor Alan Boyd, President and CEO of Boyds, spoke to Cell and Gene Therapy Insights to share his views on gene therapy trends and innovation in the rare and ultra-rare disease spaces.
Eamonn McGowran explains developments in regulation for medical devices in Med-Tech Innovation article
An article published in Med-Tech Innovation and authored by Eamonn McGowran, explains the developments in regulation for Medical devices.
Dr Karen Mullen interviewed for pharmaphorum article
Dr Karen Mullen, Chief Medical Officer at Boyds, recently sat down with pharmaphorum, a leading online destination for healthcare and pharmaceutical industry news.
Boyds regulatory affairs article published by Drug Discovery World
An article authored by Dr Julie Warner, Vice President of Regulatory Affairs, has been featured by Drug Discovery World – the multi-platform global voice for the drug discovery community.
Boyds article published by Clinical Leader
An article authored by Dr Harriet Gray Stephens, Pharmaceutical Physician in Boyds’ Clinical and Medical Affairs team has been featured by Clinical Leader – a leading online resource that covers clinical research and trials and aims to streamline research by connecting sponsors and service providers. The article, titled: ‘How to make trials more successful with […]
Boyds bolsters regulatory affairs team with key appointment
We are delighted to announce the appointment of experienced regulatory affairs professional and cell and gene therapy expert Dr Patrick Ginty. With 17 years’ R&D and regulatory affairs experience in regenerative medicine and cell and gene therapy products, Patrick joins Boyds as Senior Director of Regulatory Affairs. Most recently, Patrick was Head of Regulatory Affairs […]
Boyds expands regulatory affairs team with experienced senior hire of Katherine Bowen
We are delighted to announce the appointment of experienced regulatory affairs professional Katherine Bowen in response to a rise in demand for our specialist regulatory services. With more than 14 years’ experience in regulatory affairs across both mid to large pharma and consultancies, Katherine joins Boyds as Senior Director of Regulatory Affairs. Katherine joins Boyds […]
Boyds US Office: celebrating one year
Boyds took the bold step to open its US office in September 2021, appointing Katy Rudnick as Vice President and Head of US Regulatory Affairs to head up the (then) newly established expansion office. One year on, we reflect on the last twelve months and look to the future. Boyds had already built up an […]
Further growth for Boyds’ clinical operations team with hire of Chris Moore
We are delighted to announce the appointment of Chris Moore as Clinical Project Manager to support growing demand for our specialist clinical trial expertise. As Clinical Project Manager at Boyds, Chris will provide project management support across a range of client projects, including carrying out ethics submissions, project managing clinical trials in the UK, contributing […]
